Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers

[1] Birnkrant DJ(2018)Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management Lancet Neurol 17 251-267

[2] Bushby K(2018)Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophy Pediatrics. 142 S5-16

[3] Bann CM(2014)A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy Neuromuscul Disord 24 482-491

[4] Apkon SD(2018)Current and emerging therapies for Duchenne muscular dystrophy Curr Treat Options Neurol 20 31-144

[5] Blackwell A(2006)Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule Muscle Nerve 34 135-474

[6] Brumbaugh D(2011)A population-based study of dystrophin mutations in Canada Can J Neurol Sci 38 465-506

[7] Case LE(1989)The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion Am J Hum Genet 45 498-95

[8] Clemens PR(1988)An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus Genomics. 2 90-850

[9] Hadjiyannakis S(2005)Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect Am J Phys Med Rehabil 84 843-1347

[10] Pandya S(2000)A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy Muscle Nerve 23 1344-645

[1] Birnkrant DJ(2018)Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management Lancet Neurol 17 251-267

[2] Bushby K(2018)Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophy Pediatrics. 142 S5-16

[3] Bann CM(2014)A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy Neuromuscul Disord 24 482-491

[4] Apkon SD(2018)Current and emerging therapies for Duchenne muscular dystrophy Curr Treat Options Neurol 20 31-144

[5] Blackwell A(2006)Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule Muscle Nerve 34 135-474

[6] Brumbaugh D(2011)A population-based study of dystrophin mutations in Canada Can J Neurol Sci 38 465-506

[7] Case LE(1989)The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion Am J Hum Genet 45 498-95

[8] Clemens PR(1988)An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus Genomics. 2 90-850

[9] Hadjiyannakis S(2005)Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect Am J Phys Med Rehabil 84 843-1347

[10] Pandya S(2000)A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy Muscle Nerve 23 1344-645